[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Immunology](https://durgical.com/en/immunology/) › [Cytokines and molecules](https://durgical.com/en/immunology/areas/molecules/) › BAFF and APRIL: survival signals for B cells and plasma cells

# BAFF and APRIL: survival signals for B cells and plasma cells

- Molecule

B cells and plasma cells die without a steady survival signal; too much signal keeps self-reactive B cells alive, too little leaves antibody deficiency.

Updated Nov 15, 2026

## Key points

- BAFF-R → naive B survival; TACI → class switch/T-independent; BCMA → plasma cells.
- High BAFF → self-reactive B cells survive (lupus, Sjögren); [belimumab](https://durgical.com/en/pharmacology/belimumab/) blocks BAFF.
- BCMA is a myeloma target.
- TNFRSF13B (TACI) variants in some [CVID](https://durgical.com/en/conditions/common-variable-immunodeficiency/).

On this page

- The basics Key points
- What it is
- How to think about it
- Key facts
- Step by step
- Ligands and receptors
- Common traps
- Elsewhere in DurgiPedia

- Clinical Clinical notes

- Study Test yourself

- Connections Connections

## What it is

BAFF (B-cell activating factor, also called BLyS) and APRIL are TNF-family cytokines made mainly by myeloid and stromal cells. Through three receptors, BAFF-R, TACI and BCMA, they keep naive B cells alive, support class switching and maintain long-lived plasma cells. High BAFF is found in lupus and [Sjögren disease](https://durgical.com/en/conditions/sjogren-disease/), TACI variants are common in common variable immunodeficiency, and BCMA is a major target in [multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/).

## How to think about it

BAFF is a limited food supply that B cells compete for: normal cells outcompete weakly-signalling self-reactive ones, which starve. Flood the system with BAFF (lupus, Sjögren, after B-cell depletion) and even the self-reactive cells are fed; APRIL is the separate food that keeps marrow plasma cells alive.

## Key facts

- BAFF levels rise when B cells are depleted, which may help self-reactive B cells re-emerge after [rituximab](https://durgical.com/en/pharmacology/rituximab/).
- Transitional self-reactive B cells compete poorly for BAFF; excess BAFF lets them survive (a peripheral tolerance checkpoint).
- APRIL produced in bone-marrow niches helps keep plasma cells alive for years.

## Step by step

- Myeloid and stromal cells release BAFF; marrow niche cells supply APRIL.
- New transitional B cells compete for BAFF through BAFF-R; self-reactive ones, with weaker signals, lose and die.
- Survivors mature into naive B cells, still needing BAFF-R signals to stay alive.
- Activated and marginal-zone B cells use TACI for class switching and T-independent responses.
- Long-lived plasma cells use BCMA to receive APRIL in bone-marrow niches and survive for years.
- Excess BAFF rescues self-reactive B cells (autoimmunity); loss of BAFF-R or TACI function weakens antibody production.

## Ligands and receptors

| Receptor | Ligands | Main cells | Function and clinical link |
| --- | --- | --- | --- |
| BAFF-R (BR3) | BAFF only | Transitional and mature naive B cells | Survival of the naive B-cell pool; BAFF-R deficiency → antibody deficiency |
| TACI | BAFF and APRIL | Activated and marginal-zone B cells | T-independent responses and class switching; TNFRSF13B variants in some CVID patients |
| BCMA | APRIL (and BAFF) | Plasma cells | Survival of long-lived plasma cells in the marrow; target of [CAR-T cells](https://durgical.com/en/biochemistry/topics/gene-therapy/) and bispecifics in myeloma |

## Clinical notes

- Belimumab, an antibody against soluble BAFF, is approved for [systemic lupus erythematosus](https://durgical.com/en/conditions/systemic-lupus-erythematosus/) and [lupus nephritis](https://durgical.com/en/conditions/lupus-nephritis/).
- Blockers of both BAFF and APRIL are being studied in [IgA nephropathy](https://durgical.com/en/conditions/iga-nephropathy/) and lupus.
- Multiple myeloma: BCMA-directed CAR-T cells, bispecific [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) and antibody–drug conjugates are in clinical use.
- TACI variants are a risk factor for CVID but are also found in healthy people, so they are not diagnostic alone.

## Common traps

- **BAFF and APRIL are made by T cells**: they come mainly from myeloid and stromal cells, which is why B cells depend on their surroundings.
- **A TACI variant confirms CVID**: TNFRSF13B variants raise risk but are also found in healthy people, so they are not diagnostic alone.
- **Rituximab depletes plasma cells and so removes all antibody**: CD20 is absent on plasma cells, and BCMA-dependent long-lived ones persist.
- **BCMA is a B-cell marker found on naive B cells**: BCMA is mainly on plasma cells, which makes it a target in multiple myeloma.

## Test yourself

Think of the answer, then tap the question to see it.

## Why does excess BAFF promote autoimmunity?

Self-reactive transitional B cells normally lose the competition for scarce BAFF and die; when BAFF is plentiful they survive and can make autoantibodies.

## Why is BCMA a better target than CD20 in multiple myeloma?

Myeloma cells are plasma cells, which carry BCMA (their APRIL survival receptor) but usually lack CD20.

## After rituximab, BAFF levels rise. Why might this matter for relapse?

With fewer B cells competing, more BAFF per cell is available, which may help self-reactive B cells survive as the pool regenerates.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/immunology/baff-and-april-survival-signals-for-b-cells-and-plasma-cells/)

## Elsewhere in DurgiPedia

- [Multiple myeloma](https://durgical.com/en/general-pathology/multiple-myeloma/)

## Connections

## Related 7

- [B cell and plasma cell](https://durgical.com/en/immunology/b-cell-and-plasma-cell/)
- [B-cell activation, class switching and affinity maturation](https://durgical.com/en/immunology/b-cell-activation-class-switching-and-affinity-maturation/)
- [Extrafollicular and germinal-centre B-cell responses](https://durgical.com/en/immunology/extrafollicular-and-germinal-centre-b-cell-responses/)
- [Immune tolerance and how autoimmunity begins](https://durgical.com/en/immunology/immune-tolerance-and-how-autoimmunity-begins/)
- [B-cell (antibody) deficiencies: XLA, CVID, IgA deficiency, hyper-IgM](https://durgical.com/en/immunology/b-cell-deficiencies-xla-cvid-iga-deficiency-hyper-igm/)
- [Autoantibodies: the table to know](https://durgical.com/en/immunology/autoantibodies-the-table-to-know/)
- [Monoclonal antibodies and biologics: naming and targets](https://durgical.com/en/immunology/monoclonal-antibodies-and-biologics-naming-and-targets/)

## Related conditions 4

- [Systemic lupus erythematosus](https://durgical.com/en/conditions/systemic-lupus-erythematosus/)
- [Lupus nephritis](https://durgical.com/en/conditions/lupus-nephritis/)
- [Sjögren disease](https://durgical.com/en/conditions/sjogren-disease/)
- [Common variable immunodeficiency (CVID)](https://durgical.com/en/conditions/common-variable-immunodeficiency/)

## In Pharmacology 1

- [Belimumab](https://durgical.com/en/pharmacology/belimumab/)

[← All of immunology](https://durgical.com/en/immunology/)

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: [TNFRSF13B gene](https://medlineplus.gov/genetics/gene/tnfrsf13b/) (MedlinePlus Genetics, US National Library of Medicine, 2024); [Common variable immune deficiency](https://medlineplus.gov/genetics/condition/common-variable-immune-deficiency/) (MedlinePlus Genetics, US National Library of Medicine, 2024); [Autoimmune diseases](https://medlineplus.gov/ency/article/000816.htm) (MedlinePlus, US National Library of Medicine, 2024).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/immunology/baff-and-april-survival-signals-for-b-cells-and-plasma-cells/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/immunology/baff-and-april-survival-signals-for-b-cells-and-plasma-cells/
